<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Dominant <z:e sem="disease" ids="C0019247" disease_type="Disease or Syndrome" abbrv="">genetic disorders</z:e>, particularly those due to a mutant protein exerting a dominant-negative effect, present a unique challenge for gene therapy </plain></SENT>
<SENT sid="1" pm="."><plain>Unlike recessive disorders, where expression of a <z:mp ids='MP_0002169'>wild-type</z:mp> gene is likely to be sufficient to ameliorate disease pathology, therapies for dominant disorders are likely to require suppression of the disease allele while maintaining expression of its <z:mp ids='MP_0002169'>wild-type</z:mp> counterpart </plain></SENT>
<SENT sid="2" pm="."><plain><z:e sem="disease" ids="C0024796" disease_type="Disease or Syndrome" abbrv="MFS|MFS1">Marfan syndrome</z:e>, the most common <z:e sem="disease" ids="C0019247" disease_type="Disease or Syndrome" abbrv="">genetic disorder</z:e> of the connective tissue, is caused by mutant fibrillin 1 protein exerting a dominant-negative effect </plain></SENT>
<SENT sid="3" pm="."><plain>Antisense hammerhead ribozymes--small catalytic <z:chebi fb="40" ids="33697">RNAs</z:chebi> capable of targeting and cleaving specific <z:chebi fb="40" ids="33697">RNA</z:chebi> molecules--appear to offer promise in the development of a therapy for <z:e sem="disease" ids="C0024796" disease_type="Disease or Syndrome" abbrv="MFS|MFS1">Marfan syndrome</z:e> </plain></SENT>
</text></document>